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Abstract
Background
The management of patients with non-valvular atrial fibrillation (NVAF) with rate-lowering or
anti-arrhythmic drugs has markedly changed over the last decade, but it is unknown how
these changes have affected patients with NVAF with a permanent pacemaker (PPM).
Methods
Through Danish nationwide registries, patients with NVAF and a PPM were identified from
2001 to 2012. Changes in concomitant pharmacotherapy and comorbidities were tested
using the Cochran–Armitage trend test and linear regression. Patients with NVAF were
identified to calculate the proportional amount of PPM implants.
Results
A total of 12,231 NVAF patients with a PPM were included in the study, 55.6% of which were
men. Median age was 78 years (interquartile range 70–84). From 2001 to 2012, the number
of NVAF patients with a PPM increased from 850 to 1344, while the number of NVAF patients
increased from 67,478 to 127,261. Thus, the proportional amount of NVAF patients with a
PPM decreased from 1.3% to 1.1% (p = 0.015). Overall 45.9% had atrial fibrillation (AF) dura-
tion less than one year and the proportion declined from 55.5% to 42.4% (p <0.001). Diabe-
tes mellitus increased from 7.2% to 16.8% (p <0.001). Heart failure (HF) decreased from
36.7% to 29.3% (p = 0.010) and ischemic heart disease (IHD) decreased from 32.4% to
26.1% (p <0.001). Beta-blocker use increased from 38.1% to 58.0% (p <0.001), while digoxin
and anti-arrhythmic drug use decreased over time.
Conclusion
From 2001 to 2012, the absolute number of NVAF patients with a PPM increased while the
proportional amount decreased. The number of NVAF patients receiving a PPM within one
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year of AF diagnosis decreased. The prevalence of DM increased, while the prevalence of
HF and IHD was high but decreasing. The use of beta-blockers increased markedly, while
use of digoxin and anti-arrhythmic drugs decreased over time.
Introduction
Treatment strategies of non-valvular atrial fibrillation (NVAF) have changed over the last
decade, potentially resulting in changes to the need for permanent pacemaker (PPM) implan-
tation [1–4]. Various conditions warrant a PPM in patients with NVAF to prevent symptoms
and syncope, death, and to improve quality of life, the most common being symptomatic bra-
dycardia induced by either sick sinus node syndrome or iatrogenic due to the prescription of
rate-lowering or anti-arrhythmic drugs [5–8]. Atrial fibrillation (AF) is the most common
arrhythmia and during the last 10 years emerging evidence has estimated the prevalence in the
adult population to be around 2.3–3.4% with an increasing incidence [9,10]. Immigrant stud-
ies and prevalence studies suggests that AF is more common in the Nordic countries [11,12].
Furthermore, the incidence of AF in Denmark has increased threefold during the last 30 years
[13]. Despite of these data, it is unknown to which extent the increase in AF incidence have
affected the use of PPM implants in Denmark. Secondly, it is unknown how the patients with
NVAF and PPM are treated at the time of device implantation. Furthermore, it has not been
described whether the temporal changes in comorbidity burden and use of pharmacotherapy
during the last decade among these patients reflect the general trends among NVAF patients.
The aim of this study was to investigate the temporal trend of the proportional amount of
PPM implants in NVAF patients and to investigate the temporal changes in patient demo-
graphics, concomitant use of pharmacotherapy, cardiovascular surgical procedures, and
comorbidities in NVAF patients with a PPM from 2001 to 2012.
Methods
All Danish residents are, at birth or migration, provided with a unique civil registration num-
ber enabling crosslinking between nationwide registers. In this retrospective nationwide
cohort study, The Civil Registration System, The Danish National Patient Register (DNPR),
The Integrated Database for Labor Market Research Database, and The Danish Drug Statistical
Registry were used to identify patient demographics, medical procedures, comorbidities,
annually income, educational level, and concomitant pharmacotherapy. The Civil Registration
System holds data on age, sex, and vital status. DNPR holds information on every hospital
admission in Denmark since 1977. Each hospitalization is registered at date of admission and
contains information on the date of discharge combined with one primary diagnosis and, if
applicable, one or more secondary diagnoses defined by the International Classification of Dis-
eases; the 8th (ICD-8) or the10th revision (ICD-10) since 1994. DNPR also holds information
on medical procedures including PPM implantations performed in Denmark. Procedures
have been registered since 1996 and coded by the Nordic Classification of Surgical Procedures
(NCSP). The Integrated Database for Labor Market Research Database contains information
on annual household income since 1980 and information on the highest individually achieved
educational level. The Danish Drug Statistical Registry holds information on all drug prescrip-
tions redeemed since 1995. Each drug is classified by the international Anatomical Therapeutic
Chemical (ATC) classification [14].
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Study cohort
Patients with NVAF were included in the study on the date of PPM implantation from 1st Jan-
uary, 2001 to 31st December 2012. Single chamber atrial PPM, single chamber ventricular
PPM, dual chamber PPMs, cardiac resynchronization therapy (CRT) with pacemakers
(CRT-P), and CRT with implantable cardioverter-defibrillator (CRT-D) were identified using
NCSP procedure codes. The NCSP codes have previously been validated [15]. NVAF was
defined as the diagnosis of AF by ICD-10 or ICD-8 codes I48, 42794, 42795 with absence of
rheumatic valve disease and mechanical valve replacement as previously done [16]. Data on
AF type (paroxysmal, persistent or permanent) was unavailable. The patients were divided
into groups by year of PPM implantation date between 2001 and 2012. Annually income was
defined as household income after taxation and interest and for the value of the Danish
currency in 2009. Income was estimated as an average of the year of PPM and up to 5 years
prior. For categorical analysis, income was grouped into four groups; < 1st. quartile, 1st-2nd
quartile, 2nd-3rd quartile, and3rd quartile. Income groups were also divided at age65 years
and<65 years, to consider for those in the working age. Three educational levels were grouped
as follows: basic and high school, vocational education, and higher education (university
degree). AF duration was identified as the time between date of first AF diagnosis and date of
PPM implantation. NCSP codes were used to identify coronary artery bypass grafting, percuta-
neous coronary intervention, radiofrequency catheter ablations for AF, and cardioversion.
ICD-10 codes were used to identify heart failure (HF), ischemic heart disease (IHD), ischemic
stroke, chronic obstructive pulmonary disease, sick sinus node syndrome, atrio-ventricular
(AV) block of all types, and unspecified bradycardia.
Procedures and comorbidities were identified for each patient within 5 years prior to the
date of inclusion (baseline date). ATC codes were used to identify prescription drugs
claimed within 180 days prior to date of inclusion for beta-blockers, digoxin, class 4 calcium
channel blockers (diltiazem and verapamil), amiodarone, class 1C (flecainide and propafe-
none), non-loop diuretics, loop-diuretics, calcium channel blockers, renin-angiotensin sys-
tem inhibitors, and oral anticoagulants (antagonists and non-vitamin-K antagonists).
Anti-diabetic drugs were used as a proxy for diabetes mellitus (DM). All ICD-10 codes,
ICD-8 codes, NCSP codes, and ATC codes used are available in S2 Table. Three subgroup
analyses of patients with IHD, DM, and HF were performed. Besides the study cohort, the
total number of alive patients with NVAF for each year from 2001 to 2012 was identified.
These were defined as patients with NVAF and the AF diagnosis on a date before or within
2001 adding new incident patients with NVAF each subsequent year up to and including
2012.
Statistical analysis
Categorical data were presented as counts with percentages and statistical differences were
tested using a Chi-squared test. Continuous variables were presented as medians with inter-
quartile range (IQR) and statistical differences were tested using a Kruskal-Wallis test. The
proportional amount of NVAF patients with a PPM was calculated by the number of NVAF
patients with a PPM out of the total number of patients with NVAF for each year. Trends in
categorical variables were tested for using a Cochran–Armitage test and for continuous
variables, trends were tested for using linear regression analysis. A two-sided p-value <0.05
was considered statistically significant. Data management and statistical analyses were con-
ducted using R statistics (R Core Team (2016). R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-
project.org/).
Atrial fibrillation & pacemaker time trends
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Ethics
In Denmark, retrospective register studies do not require approval from ethics committees.
The Danish Data Protection Agency approved this study (ref. no.: 2007-58-0015/GEH-2014-
016 I-Suite no.: 02734). Data were made available to us in an anonymized format such that spe-
cific individuals could not be identified.
Results
Study population
A total of 12,231 patients with NVAF and PPMs were included between 2001 and 2012
(Fig 1). The overall median age (IQR) was 78 (70–84) with most patients being men (55.6%,
n = 6,805). The median (IQR) duration of AF prior to PPM implant was 1.39 years (0.07–
5.09) and a total of 45.9% (n = 5,615) of the patients received a PPM within the first
year of their AF diagnosis. The PPM type mostly used was the dual chamber pacemaker
accounting for 39.4% (n = 4,823). Overall prevalence of HF, IHD, and DM was 33.6%
(n = 4,104), 29.6% (n = 3,621) and 13.9% (n = 1,704), respectively. The most common bra-
dyarrhythmia diagnosis was sick sinus node syndrome with a prevalence of 43.7% (n =
5,346) (Table 1).
Fig 1. Flowchart. Flowchart inclusion of the study cohort. Stratified by year of pacemaker implantation date.
https://doi.org/10.1371/journal.pone.0195175.g001
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Table 1. Baseline characteristics.
Overall 2001 2012 P trend P value+
NVAF patients with a PPM, n 12231 850 1344
Men, n (%) 6805 (55.6) 479 (56.4) 775 (57.7) 0.003 0.030
Median age in years (IQR) 78 (70–84) 76 (69–83) 78 (71–84) <0.001 0.034
Age category, n (%) 0.011
<70 years 2853 (23.3) 222 (26.1) 288 (21.4) 0.081
70–80 years 4644 (38.0) 343 (40.4) 546 (40.6) 0.493
>80 years 4734 (38.7) 285 (33.5) 510 (37.9) 0.028
Annually household income, age 65 years (DKK), n (%) <0.001
<1 quartile (<173,650) 2668 (25.0) 237 (33.0) 210 (17.5) <0.001
1st– 2nd quartile (173,650–230,041) 2654 (24.9) 193 (26.8) 294 (24.5) 0.003
2nd– 3rd quartile (230,041–326,604) 2665 (25.0) 150 (20.9) 331 (27.6) <0.001
 3rd quartile ( 326,604) 2664 (25.0) 139 (19.3) 366 (30.5) <0.001
Educational level <0.001
Basic & high school 5048 (41.3) 314 (36.9) 586 (43.6) <0.001
Vocational 3311 (27.1) 157 (18.5) 452 (33.6) <0.001
Higher 1539 (12.6) 73 (8.6) 221 (16.4) <0.001
AF duration, n (%) <0.001
<1 year 5615 (45.9) 472 (55.5) 570 (42.4) <0.001
1–1.9 years 1144 (9.3) 89 (10.5) 125 (9.3) 0.142
2–6 years 2938 (24.0) 209 (24.6) 288 (21.4) <0.001
Median AF duration in years (IQR) 1.39 (0.07–5.09) 0.67 (0.04–3.08) 1.81 (0.12–6.58) <0.001 <0.001
Pacemaker type, n (%)
Single chamber atrial 505 (4.1) 73 (8.6) 5 (0.4) <0.001 <0.001
CRT-P 418 (3.4) 15 (1.8) 45 (3.3) 0.048 0.044
CRT-D 494 (4.0) 5 (0.6) 84 (6.2) <0.001 <0.001
Unspecified 1417 (11.6) 49 (5.8) 224 (16.7) <0.001 <0.001
Comorbidities, n (%) <0.001
DM 1704 (13.9) 61 (7.2) 226 (16.8) <0.001 <0.001
HF 4104 (33.6) 312 (36.7) 394 (29.3) 0.009 0.010
IHD 3621 (29.6) 275 (32.4) 351 (26.1) <0.001 <0.001
COPD 1318 (10.8) 65 (7.6) 151 (11.2) <0.001 <0.001
Ischemic stroke 1760 (14.4) 143 (16.8) 197 (14.7) 0.188 0.116
Bradyarrhythmia diagnosis, n (%)
Sick sinus node syndrome 5346 (43.7) 374 (44.0) 548 (40.8) 0.064 0.062
AV-block 3191 (26.1) 168 (19.8) 362 (26.9) <0.001 <0.001
Unspecified bradycardia 2210 (18.1) 142 (16.7) 173 (12.9) <0.001 <0.001
Rate-lowering drugs, anti-arrhythmic drugs, and oral anticoagulants, n (%)
Beta-blocker 6169 (50.4) 324 (38.1) 779 (58.0) <0.001 <0.001
Digoxin 3962 (32.4) 347 (40.8) 363 (27.0) <0.001 <0.001
Class 4 1087 (8.9) 130 (15.3) 87 (6.5) <0.001 <0.001
Class 1C 304 (2.5) 37 (4.4) 22 (1.6) <0.001 <0.001
Amiodarone 767 (6.3) 51 (6.0) 69 (5.1) 0.009 0.011
VKA & NOACs 5320 (43.5) 276 (32.5) 724 (53.9) <0.001 <0.001
Baseline characteristics for the overall cohort and year 2001 and 2012 (See S1 Table for every year and every covariate). Information on educational level and annually
income is missing for some individuals. Abbreviations: IQR, interquartile range. DKK, Danish krone (national currency). AF, atrial fibrillation. AV, atrioventricular.
CRT-P, Cardiac resynchronization therapy pacemaker; CRT-D, Cardiac resynchronization therapy with implantable cardiac defibrillator. COPD, chronic obstructive
pulmonary disease. HF, heart failure. IHD, ischemic heart disease. DM, diabetes mellitus. Class 4, class 4 non-dihydropyridine calcium channel blocker. VKA &
NOACs, vitamin-k antagonist & non-vitamin-k antagonists.
 P trend: P value test of trend in all years (2001–2012) using Cochran-Armitage trend test for categorical variables and a linear regression for continuous variables.
+ P value for statistical differences in all years (2001–2012) by Kruskal-Wallis test for continuous variables and Chi-squared test for categorical data.
https://doi.org/10.1371/journal.pone.0195175.t001
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Temporal trends from 2001 to 2012
The number of patients with NVAF and PPM implantations increased by 58.1% from 850
patients in 2001 to 1,344 patients in 2012 (p trend <0.001). In the same period, the total num-
ber of NVAF patients increased from 67,478 to 127,261 patients. Thus, the proportional
amount of NVAF patients with a PPM decreased from 1.3% in 2001 to 1.1% in 2012 (p
trend = 0.015) (Fig 2). From 2001 to 2012 the median (IQR) age increased from 76 (69–83) to
78 (71–84) (p trend <0.001) (Table 1). For the patients aged65 years, the annual income
increased; 2nd– 3rd quartile income group increased from 20.9% to 27.6% (p trend<0.001),
the3rd quartile income group increased from 19.3% to 30.5% (p trend<0.001). There was
no significant change in income for patients under 65 years, except for the3rd quartile
income group which also increased (S1 Table). There was a clear trend towards increased prev-
alence of higher educational level from 8.6% to 16.4% (p trend<0.001). Patients with AF dura-
tion less than one year to PPM implant decreased from 55.5% to 42.4% (p trend<0.001)
(Fig 3). The relative use of CRT increased, while single lead pacemaker decreased (Table 1).
Radiofrequency catheter ablation procedures increased from0.6% to 2.5% (p trend <0.001)
(S1 Table).
Temporal changes in comorbidities and pharmacotherapy. For important comorbidi-
ties from 2001 to 2012, an increase in prevalence of DM from 7.2% to 16.8% was observed. HF
decreased from 36.7% to 29.3% and IHD decreased from 32.4% to 26.1% (Fig 4). Among the
diagnoses associated with implantation of PPM an increase in AV block prevalence and a
decrease in unspecified bradycardia decreased was observed. No significant change in trend
Fig 2. Number of NVAF patients with a PPM and number of total NVAF population. The bars show the number of NVAF patients with pacemaker
implantations per year from 2001 to 2012. The blue line shows the prevalence of NVAF patients from 2001 to 2012. The red line shows the proportional
percentage of NVAF patients with a PPM out of the total number of NVAF patients per year.
https://doi.org/10.1371/journal.pone.0195175.g002
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for of sick sinus node syndrome was observed (Table 1). Other comorbidities are shown in
Table 1 and S1 Table.
When investigating the changes in rate-lowering and anti-arrhythmic drug use a significant
52.2% increase in beta-blocker use from 38.1% to 58.0% (p trend <0.001) was found, while the
use of digoxin decreased from 40.8% to 27.0% (p trend<0.001). For amiodarone, class 4, and
class 1C drugs the overall use was very low and a significant decrease in use in all three was
found (Fig 5). Use of oral anticoagulants increased from 32.5% to 53.9% (p trend<0.001).
Temporal trends for renin-angiotensin-system inhibitors, calcium channel blockers, loop, and
non-loop diuretics are shown in S1 Table. In three subgroup analyses for patients with IHD,
HF, and DM the same temporal trends for comorbidities and use of pharmacotherapies were
observed.
Discussion
This study reports temporal changes in NVAF patients with a PPM from 2001 to 2012. Our
main findings were: 1) The absolute number of NVAF patients with a PPM increased, while
the proportional amount of NVAF patients with a PPM decreased. 2) Almost half of the
patients with a PPM, received the implantation within the first year after AF diagnosis. How-
ever, there was a trend towards increased NVAF duration before PPM over time. 3) The preva-
lence of DM increased while the comorbidity prevalence of IHD and HF was generally high
Fig 3. Duration of AF to pacemaker implantation. The duration of AF to pacemaker implantation shown in percent in year categories; under 1 year,
1–1.9 years, and 2–6 years of AF duration. Abbreviations: AF, atrial fibrillation.
https://doi.org/10.1371/journal.pone.0195175.g003
Atrial fibrillation & pacemaker time trends
PLOS ONE | https://doi.org/10.1371/journal.pone.0195175 March 28, 2018 7 / 13
but decreasing. 4) The use of beta-blockers increased, while the use of digoxin and anti-
arrhythmic drugs decreased.
The increased number of NVAF patients with a PPM implants found in our study reflects
the worldwide trend of increased use of PPM implants [17]. However, due to the increasing
number of patients with NVAF the proportional amount of PPM implants decreased from
1.3% to 1.1% (p trend = 0.015). Prior studies have shown that the prevalence of AF patients
with PPM ranges between 7.3%–33% which is markedly higher than the percentage found in
our study. This discrepant finding could reflect differences in study cohort selection and study
design; since our study used data from an unselected nationwide cohort whereas previous
studies have been conducted cohort from a randomized controlled trial [1] and a cohort
derived from patient records from a single hospital [18]. To our knowledge, this is the first
study to have estimated the prevalence of nationwide PPMs in NVAF patients, and therefore it
is not possible to determine if PPMs are underused or excessively used in the cohort.
The proportion of patients with above median quartile income and higher education level
was found to be increasing during the study period. A recent U.S study investigated patients
with sick sinus node syndrome and PPMs from 2003 to 2013. They found that income above
median quartile had an increased risk of receiving an PPM [19], and one of their main expla-
nations for this was patient affordability of PPM. The Danish healthcare which is available free
of charge to all inhabitants independent of socioeconomic status should rule out any patient
concerns about affordability. It could be hypothesized that the proportion of AF patients with
PPM and high socioeconomic status increased either due to an overall increase in income and
Fig 4. Temporal changes of prevalence in comorbidities. Temporal changes of prevalence in comorbidities in the study population from 2001 to
2012. Abbreviations: IHD, ischemic heart disease. COPD, chronic obstructive pulmonary disease.
https://doi.org/10.1371/journal.pone.0195175.g004
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education in the AF population or due to change in which social group the physician sees fit to
undergo PPM implantation. One study looking at disparities of CRT in HF patients between
ethnicity and income [20] found that Afro-Americans and low-income patients were less likely
to undergo CRT, indicating there could be an underuse of PPMs in low-income patients.
Overall, 45.9% of the patients had PPM implantation within one year of AF diagnosis, which
suggests early demasking of significant bradyarrhythmia and therefore increased risk of early
PPM implantation after AF diagnosis. This might be due to early onset of anti-arrhythmic
drugs side effects or comorbidities associated with sinus node remodelling such as HF [18].
There was a trend towards a longer duration of AF to PPM implantation. This could be
explained by both a reduced number of conditions leading to PPM and the changes towards
rate-lowering from anti-arrhythmic treatment strategy, but also by lead time bias. Lead time
bias is introduced when patients get diagnosed with AF earlier in their life in 2012 than in
2001, hence the duration of AF has not increased only the time with the diagnosis. Previous
radiofrequency catheter ablations were rare in this cohort, but did increase over time from
under 0.6% to 2.5% which is consistent with the general trend of the AF population [21].
Temporal changes in comorbidities
There is a known association between AF and DM; up to 20% of DM patients have AF [22].
DM increases risk of conduction pathway failure and patients with DM are more likely to get a
PPM [23]. In our study, the prevalence of DM increased over time up to 16.8% in 2012. This
Fig 5. Temporal changes of prevalence in rate-lowering and anti-arrhythmic pharmacotherapy. Temporal changes of prevalence in rate-lowering
and anti-arrhythmic pharmacotherapy in the study population from 2001 to 2012. CCB is class 4 non-dihydropyridine calcium channel blockers
(diltiazem and verapamil). Class 1C is propafenone and flecainide.
https://doi.org/10.1371/journal.pone.0195175.g005
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increasing trend is expected based on increasing prevalence of DM in the Danish population
[24]. A Danish study of patients with AF from 1997 to 2006 found the prevalence of DM at
9.1% [25]. Compared to the Nordic countries, a Swedish study found a total prevalence of
19.8% from 2001 to 2007 [26]. The Swedish study only included AF patients with age above 45
years, which could be why they found a higher prevalence of DM. An overall prevalence of HF
of 36.8% was found, however, with a small decrease in prevalence over time. Two previous
Danish studies of prevalence of HF in AF patients, have ranged between 18.8% and 23.9%
[3,25] which is comparable which is comparable to the European prevalence between 22% and
42% [10]. Compared to other Nordic countries a high HF prevalence in AF was found at
46.6% in a recent study from Sweden [26]. The discrepancy can partially be explained by
design; the Swedish study included both primary care and admission diagnosis. HF is associ-
ated with sinus node remodeling and has previously been identified as an independent risk
factor for PPM [18]. This could to some extent explain the high prevalence of HF found in our
study since all the patients in our study population already had a PPM. Our finding of tempo-
ral decreasing prevalence of HF could explain the decrease in the proportional amount of
PPM implantations. The high prevalence of IHD observed in our study is in accordance with a
German study, the AFFIRM trial, the Swedish study and the overall reported prevalence of
IHD in AF ranging from 17%-46.5% [1,26–28]. Among bradycardia diagnoses indicating the
need of PPM, sick sinus node syndrome was the highest with a prevalence of 43.7%. Sick sinus
node syndrome has previously been reported at 79% of bradycardia patients requiring pace-
makers [29] which supports that sick sinus node syndrome is the most prevalent indication of
PPM in AF patients.
Temporal changes in pharmacotherapy
The use of pharmacotherapy in NVAF patients with a PPM has changed markedly over time.
Beta-blocker use increased by 52.2%, while use of digoxin, amiodarone, class 1C, and class 4
anti-arrhythmic drugs decreased. Similarly, an increased use of beta-blockers and declining
use of digoxin and anti-arrhythmic drugs has been reported in earlier in studies among Danish
patients with AF from 1995 to 2004 [3] and from 2000 to 2009 [21]. The same trend in phar-
macotherapy was also found in Swedish and U.S patients with AF [30,31] during the same
period of time, suggesting a global shift in treatment strategy. The first ACC/AHA/ESC guide-
lines for AF treatment was published in 2001. In these guidelines, no specific strategy in the
choice between rate-lowering or anti-arrhythmic drugs was recommended, thus these guide-
lines cannot explain the early shift towards increased use of beta-blockers found in this study.
The increased use of beta-blockers could be due to a “carry-over effect”, where beta-blockers
have shown benefits in patients with HF or IHD and the treatment is continued after AF diag-
nosis [3,32]. Besides the expanding indication for beta-blocker treatment, trials have favored
the treatment of AF towards the rate-lowering treatment strategy. The AFFIRM trial in 2002
concluded no benefit of rhythm control over rate control and as rate control is associated with
less side-effects this could explain the shift towards an increased use of beta-blockers and
decrease in amiodarone [1]. Later the RACE trial in 2010 concluded that strict rate control was
not superior to lenient rate control. The trial may have led to reduced dosage of rate-lowering
drugs, and thus decreasing the amount of iatrogenic brady-arrhythmias necessitating a PPM
[2]. In an observational study of ischemic patients with AF the risk of PPM increased with
both amiodarone (adjusted OR 2.14, 95% CI: 1.30–3.54) and digoxin use (adjusted OR 1.78,
95% CI 1.37–2.31) [5]. Since both amiodarone and digoxin use decreased over time in our
study this could to some extend explain the decrease in the proportional amount of NVAF
patients with a PPM.
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Strengths and limitations
The registries used for this study comprise an unselected population of patients and are not
affected by selection bias to certain hospital centres, health insurance systems or age groups.
Thus, this study data reflects real clinical practice on a nationwide scale. Despite these
strengths, there were some limitations: the non-availability of a precise indication for PPM
implantation, and thus no data on the underuse or excessively use of PPM implantation in the
NVAF cohort. Other limitations included frequency of AF episodes and AF type (paroxysmal,
persistent or permanent), indication for pharmacotherapy, and adverse reactions. Absence of
data on HbA1c might have excluded undiagnosed DM.
Conclusion
From 2001 to 2012, the absolute number NVAF patients with a PPM increased while the pro-
portional amount decreased. The number of patients who received a PPM within one year of
AF diagnosis decreased. The prevalence of DM increased, while the prevalence of IHD and HF
was high but decreasing. The use of beta-blockers increased markedly, while use of digoxin
and anti-arrhythmic drugs decreased over time. These findings provide key knowledge of
NVAF patients with a PPM.
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